- Report
- September 2025
- 254 Pages
Global
From €4575EUR$4,950USD£3,814GBP
- Report
- September 2025
- 380 Pages
Global
From €4575EUR$4,950USD£3,814GBP
- Report
- August 2025
- 383 Pages
Global
From €4575EUR$4,950USD£3,814GBP
- Report
- July 2024
- 335 Pages
Global
From €4575EUR$4,950USD£3,814GBP
- Report
- February 2022
- 155 Pages
Global
From €4436EUR$4,799USD£3,698GBP
- Report
- November 2026
Global
From €600EUR$695USD£518GBP
- Report
- November 2026
Global
From €600EUR$695USD£518GBP
- Report
- November 2026
Global
From €600EUR$695USD£518GBP
- Report
- November 2026
Global
From €300EUR$348USD£259GBP
- Report
- August 2023
- 267 Pages
Global
From €2150EUR$2,492USD£1,855GBP
- Report
- May 2022
- 50 Pages
Global
From €500EUR$579USD£431GBP
- Report
- November 2025
- 160 Pages
Global
From €2588EUR$2,800USD£2,157GBP
- Report
- November 2025
- 120 Pages
Global
From €3050EUR$3,300USD£2,543GBP
- Report
- October 2023
- 420 Pages
Global
From €2680EUR$2,900USD£2,234GBP
- Drug Pipelines
- August 2023
- 400 Pages
China
From €2773EUR$3,000USD£2,311GBP
- Report
- May 2022
- 510 Pages
Global
From €2773EUR$3,000USD£2,311GBP
- Report
- September 2023
- 141 Pages
Global
From €2080EUR$2,250USD£1,734GBP
- Report
- August 2025
- 1300 Pages
Global
From €3882EUR$4,200USD£3,236GBP
- Report
- November 2024
- 600 Pages
Global
From €3050EUR$3,300USD£2,543GBP
- Report
- September 2024
- 210 Pages
Global
From €2218EUR$2,400USD£1,849GBP

The Monoclonal Antibodies market is a subset of the biotechnology industry that focuses on the production and use of monoclonal antibodies (mAbs). mAbs are laboratory-produced proteins that are designed to bind to specific targets, such as proteins, cells, or tissues. They are used in a variety of applications, including diagnostics, therapeutics, and research.
The market for mAbs is growing rapidly, driven by advances in biotechnology and the increasing demand for personalized medicine. mAbs are used in a variety of treatments, including cancer, autoimmune diseases, and infectious diseases. They are also used in research to develop new treatments and to improve existing treatments.
The market for mAbs is highly competitive, with many companies offering a wide range of products. Major players in the market include AbbVie, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Eli Lilly, Genentech, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. These companies are investing heavily in research and development to develop new mAbs and to improve existing products.
In conclusion, the Monoclonal Antibodies market is an important part of the biotechnology industry, with many companies investing heavily in research and development to develop new products and improve existing treatments. Major players in the market include AbbVie, Amgen, AstraZeneca, Show Less Read more